OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
30045258

Anhui Sunhere Pharmaceutical Excipients Co Ltd

PharmaceuticalsVerified

Anhui Sunhere Pharmaceutical Excipients Co Ltd maintains a strong liquidity position with a current ratio of 4.14, indicating the company can easily cover its short-term liabilities with its short-term assets. However, the company has a negative net cash position after subtracting total debt, which introduces a medium liquidity risk. The debt-to-equity ratio of 0.32 suggests a relatively conservative capital structure, with a moderate reliance on debt financing. The company's profitability is reflected in a return on equity (ROE) of 17.54% and a return on assets (ROA) of 10.31%, both of which are strong indicators of efficient use of equity and assets to generate profit. These metrics suggest the company is performing well compared to the industry's preferred metrics, though direct comparisons to cohort medians are not available in the current dataset. Geographically and segment-wise, the company's exposure is not explicitly detailed in the available data. However, the company operates primarily in the pharmaceutical excipients market, which is a critical component of the broader pharmaceutical industry. The lack of detailed segment or geographic breakdown limits the ability to assess revenue concentration or diversification. The company's growth trajectory is not explicitly outlined in the available data, but the operating cash flow of 191.99 million CNY and free cash flow of 114.42 million CNY suggest a healthy cash-generating business. Analysts have provided a consistent price target of 15.60 CNY, indicating a stable outlook for the company's stock. The company faces a medium liquidity risk and a low dilution risk. The risk assessment indicates that the company is not currently under significant pressure to issue new shares, and there are no immediate signs of dilution. The capital structure remains stable, and the company has not made any recent adjustments that would significantly alter its valuation. There are no recent filings or transcripts available in the dataset that would indicate significant changes in the company's operations or strategy. The company appears to be maintaining a steady course, with no major events reported in the latest available data.

30-day price · 300452(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyAnhui Sunhere Pharmaceutical Excipients Co Ltd
Ticker300452.SZ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Anhui Sunhere Pharmaceutical Excipients Co Ltd produces and sells pharmaceutical excipients, which are inactive substances used as carriers for the active ingredients in medications.

Classification. The company is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry with a confidence level of 0.92.

Anhui Sunhere Pharmaceutical Excipients Co Ltd maintains a strong liquidity position with a current ratio of 4.14, indicating the company can easily cover its short-term liabilities with its short-term assets. However, the company has a negative net cash position after subtracting total debt, which introduces a medium liquidity risk. The debt-to-equity ratio of 0.32 suggests a relatively conservative capital structure, with a moderate reliance on debt financing. The company's profitability is reflected in a return on equity (ROE) of 17.54% and a return on assets (ROA) of 10.31%, both of which are strong indicators of efficient use of equity and assets to generate profit. These metrics suggest the company is performing well compared to the industry's preferred metrics, though direct comparisons to cohort medians are not available in the current dataset. Geographically and segment-wise, the company's exposure is not explicitly detailed in the available data. However, the company operates primarily in the pharmaceutical excipients market, which is a critical component of the broader pharmaceutical industry. The lack of detailed segment or geographic breakdown limits the ability to assess revenue concentration or diversification. The company's growth trajectory is not explicitly outlined in the available data, but the operating cash flow of 191.99 million CNY and free cash flow of 114.42 million CNY suggest a healthy cash-generating business. Analysts have provided a consistent price target of 15.60 CNY, indicating a stable outlook for the company's stock. The company faces a medium liquidity risk and a low dilution risk. The risk assessment indicates that the company is not currently under significant pressure to issue new shares, and there are no immediate signs of dilution. The capital structure remains stable, and the company has not made any recent adjustments that would significantly alter its valuation. There are no recent filings or transcripts available in the dataset that would indicate significant changes in the company's operations or strategy. The company appears to be maintaining a steady course, with no major events reported in the latest available data.
Key takeaways
  • Anhui Sunhere Pharmaceutical Excipients Co Ltd has a strong liquidity position with a current ratio of 4.14.
  • The company's ROE of 17.54% and ROA of 10.31% indicate strong profitability and efficient use of assets.
  • The company maintains a conservative capital structure with a debt-to-equity ratio of 0.32.
  • Analysts have provided a consistent price target of 15.60 CNY, suggesting a stable outlook for the company's stock.
  • The company faces a medium liquidity risk and a low dilution risk.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$942.8M
Gross profit$299.3M
Operating income$199.0M
Net income$176.6M
R&D
SG&A
D&A
SBC
Operating cash flow$192.0M
CapEx-$40.7M
Free cash flow$114.4M
Total assets$1.71B
Total liabilities$706.2M
Total equity$1.01B
Cash & equivalents
Long-term debt$325.5M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.01B
Net cash-$325.5M
Current ratio4.1
Debt/Equity0.3
ROA10.3%
ROE17.5%
Cash conversion1.1%
CapEx/Revenue-4.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric300452Activity
Op margin21.1%18.2% medp25 18.2% · p75 24.6%above median
Net margin18.7%14.7% medp25 11.7% · p75 28.1%above median
Gross margin31.7%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-4.3%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity32.0%71.3% medp25 19.0% · p75 91.7%below median
Observations
IR observations
Mean price target15.60 CNY
Median price target15.60 CNY
High price target15.60 CNY
Low price target15.60 CNY
Source: analysis-pipeline (hybrid)Generated: 2026-05-21 03:16 UTCJob: 94ea1f2a